Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.85 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.85 |
| ▸ | TUBB | P07437 | 5/20 | 0.85 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.85 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.85 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.85 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.85 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.85 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.85 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.85 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.85 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.85 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.85 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.85 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.85 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.85 |
| ▸ | TP53 | P04637 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinepidine SCHEMBL29385187 | 1.00 | LMNA (0.85) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Vinepidine SCHEMBL29376135 | 0.98 | MAPT (0.85) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Vinepidine SCHEMBL4076 | 0.98 | MAPT (0.85) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Roseamine SCHEMBL30368397 | 0.94 | MAPT (0.85) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Roseamine SCHEMBL10059227 | 0.94 | MAPT (0.85) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Vincristine SCHEMBL18402663 | 0.92 | LMNA (1.00) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Vincristine SCHEMBL4769981 | 0.92 | LMNA (1.00) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Vincristine SCHEMBL19522762 | 0.92 | LMNA (1.00) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Vincristine SCHEMBL15866613 | 0.92 | LMNA (1.00) | LMNAHIF1ACYP3A4TUBB4ATUBB | |
| Vincristine SCHEMBL15474330 | 0.92 | LMNA (1.00) | LMNAHIF1ACYP3A4TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 965 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| EP-3191114-B1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | UNIV MISSISSIPPI STATE (US) | 2021-03-03 | — | — | EP | claimed |
| EP-3706798-A1 | CONJOINT THERAPIES FOR IMMUNOMODULATION | Aurigene Discovery Technologies Limited (IN) | 2020-09-16 | — | — | EP | claimed |
| EP-2908865-B1 | ADENOVIRUS EXPRESSING A FAS-CHIMERA AND USE THEREOF IN CANCER TREATMENT METHODS | VASCULAR BIOGENICS LTD (IL) | 2018-10-03 | — | — | EP | claimed |
| EP-2923703-B1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO INC (US) | 2018-09-19 | — | — | EP | claimed |
| EP-3368081-A1 | TREATMENT OF CANCER WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | IO Therapeutics, Inc. (US) | 2018-09-05 | — | — | EP | claimed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | claimed |
| WO-2017075612-A1 | TREATMENT OF CANCER WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES | Io Therapeutics, Inc. (US) | 2017-05-04 | — | — | WO | claimed |
| EP-2358697-B1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER. | CELGENE CORP (US) | 2015-10-21 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-1846678-A | Anticancer sustained-release injection | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1839817-A | Anticancer sustained-release injection containing taxane | JINAN SHUAIHUA MEDICINE TECHNO (CN) | 2006-10-04 | — | — | CN | claimed |
| CN-1824314-A | Slow-release agent containing hormone anticancer medicine | JINAN KANGQUAN MEDICINE SCI & (CN) | 2006-08-30 | — | — | CN | claimed |
| CN-1733302-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | claimed |
| CN-1686544-A | Anti entity tumour medicinal composition containing plant alkaloid | SHANDONG LANJIN BIOLOG ENGINEE (CN) | 2005-10-26 | — | — | CN | claimed |
| CN-1686553-A | Anti entity tumour medicinal composition | SHANDONG LANJIN BIOLOG ENGINEE (CN) | 2005-10-26 | — | — | CN | claimed |
| CN-1679949-A | Anticarcinogenic internal implant agent | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1676165-A | In vivo slow-releasing anticancer medicinal composition | LANJIN BIOENGINEERING CO LTD S (CN) | 2005-10-05 | — | — | CN | claimed |
| US-20050084906-A1 | Novel anti-IGF-IR antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-21 | — | — | US | claimed |
| US-20020094991-A1 | Methods and compositions for treating microtubule-mediated viral infections and lesions | RAINBOW RESEARCH | 2002-07-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050084906-A1 | Novel anti-IGF-IR antibodies and uses thereof | IGF1R, EGFR, IRS1 | LMNA 3528/4885HIF1A 754/4885CYP3A4 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.